Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a study of metastatic colorectal cancer patients who received 5-FU-based first-line chemotherapy, those with BRAF V600E mutations had reduced progression-free survival (4.3mo vs. 12.5mo, HR:4.9, 95… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Of metastatic colorectal cancer patients treated with bevacizumab-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In metastatic colorectal cancer patients with wildtype KRAS status who received cetuximab therapy, those with a BRAF V600E mutation had reduced progression-free survival (8.0wk vs. 31.4wk, P=0.001, lo… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with second-line or higher cetuximab therapy in combination with standard ch… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 44 metastatic colorectal cancer patients who recieved FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 metastatic colorectal cancer patients, patients with a KRAS exon 2 mutation (32/92) treated with cetuximab as salvage therapy (second-line therapy or higher) in combina… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In colorectal cancer patients treated with salvage cetuximab therapy in combination with chemotherapy, PIK3CA mutations were associated with reduced progression-free survival (2.5mo vs. 3.9mo, HR:2.1,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC